Literature DB >> 28937546

A Randomized, Nonblind, Naturalistic Comparison of Efficacy and Cognitive Outcomes With Right Unilateral, Bifrontal, and Bitemporal Electroconvulsive Therapy in Schizophrenia.

Aniket Bansod, Sushma S Sonavane, Nilesh B Shah, Avinash A De Sousa, Chittaranjan Andrade.   

Abstract

BACKGROUND: There is little literature on the relative efficacy and cognitive safety of right unilateral (RUL), bifrontal (BF), and bitemporal (BT) electroconvulsive therapy (ECT) in schizophrenia.
METHODS: We present a randomized, nonblind, naturalist comparison of a fixed course of 8 moderately high-dose RUL (n = 24), threshold BF (n = 27), and threshold BT (n = 31) ECT in patients with schizophrenia. Assessments included the Positive and Negative Syndrome Scale (PANSS), the Wechsler Memory Scale-Revised, and an autobiographical memory interview. A completer analysis was planned and conducted to capture the cognitive outcomes.
RESULTS: The sample as a whole improved significantly on all efficacy outcomes and deteriorated significantly on all cognitive outcomes. The primary efficacy outcome, improvement in PANSS total scores, did not differ significantly across groups. The PANSS positive score (but no other subscale score) improved significantly less with RUL relative to BF and BT ECT. For autobiographical memory and for almost all Wechsler Memory Scale subtests, including memory quotient (the primary adverse effect outcome), BT ECT was associated with greater impairment than RUL or BF ECT. Importantly, all statistically significant differences between treatments were clinically small in magnitude.
CONCLUSIONS: In patients with schizophrenia who receive a fixed course of 8 ECTs, threshold BT ECT is associated with greater cognitive impairment across a range of measures, and moderately high-dose RUL ECT is associated with poorer efficacy against positive symptoms. Threshold BF ECT exhibits the best efficacy-cum-neurocognitive safety profile. All differences between groups, however, are small and perhaps clinically insignificant.

Entities:  

Mesh:

Year:  2018        PMID: 28937546     DOI: 10.1097/YCT.0000000000000454

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  5 in total

Review 1.  Electroconvulsive Therapy and Schizophrenia: A Systematic Review.

Authors:  Sana A Ali; Nandita Mathur; Anil K Malhotra; Raphael J Braga
Journal:  Mol Neuropsychiatry       Date:  2019-04-02

Review 2.  Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

Authors:  Masataka Wada; Yoshihiro Noda; Yusuke Iwata; Sakiko Tsugawa; Kazunari Yoshida; Hideaki Tani; Yoji Hirano; Shinsuke Koike; Daiki Sasabayashi; Haruyuki Katayama; Eric Plitman; Kazutaka Ohi; Fumihiko Ueno; Fernando Caravaggio; Teruki Koizumi; Philip Gerretsen; Takefumi Suzuki; Hiroyuki Uchida; Daniel J Müller; Masaru Mimura; Gary Remington; Anthony A Grace; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

3.  The Impact of Electroconvulsive Therapy on Negative Symptoms in Schizophrenia and Their Association with Clinical Outcomes.

Authors:  Xiaowei Tan; Donel Martin; Jimmy Lee; Phern Chern Tor
Journal:  Brain Sci       Date:  2022-04-25

Review 4.  Auditory verbal hallucinations in schizophrenia: current perspectives in brain stimulation treatments.

Authors:  Clément Nathou; Olivier Etard; Sonia Dollfus
Journal:  Neuropsychiatr Dis Treat       Date:  2019-07-24       Impact factor: 2.570

5.  Repetitive enhancement of serum BDNF subsequent to continuation ECT.

Authors:  T Vanicek; G S Kranz; B Vyssoki; A Komorowski; G Fugger; A Höflich; Z Micskei; S Milovic; R Lanzenberger; A Eckert; S Kasper; R Frey
Journal:  Acta Psychiatr Scand       Date:  2019-09-11       Impact factor: 6.392

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.